Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitis

Inflammatory Bowel Disease

Real-World Experience with Upadacitinib for Pediatric Acute Severe Ulcerative Colitis: An International Multicenter Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN

Inflamm Bowel Dis

Yerushalmy-Feler A, Spencer EA, Bergstein S, Mitrova K, Hradsky O, Bramuzzo M, Wlazlo M, Olbjørn C, Rungoe C, Weil N, Turner D, Cohen S

doi: 10.1093/ibd/izaf166

Inflammatory Bowel Disease

Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial

Lancet Gastroenterol Hepatol

Choy MC, Li Wai Suen CFD, Con D, Boyd K, Pena R, Burrell K, Rosella O, Proud D, Brouwer R, Gorelik A, Liew D, Connell WR, Wright EK, Taylor KM, Pudipeddi A, Sawers M, Christensen B, Ng W, Begun J, Radford-Smith G, Garg M, Martin N, van Langenberg DR, Ding NS, Beswick L, Leong RW, Sparrow MP, De Cruz P

doi: 10.1016/S2468-1253(24)00200-0

Inflammatory Bowel Disease

Tofacitinib versus Vedolizumab Among Bio-naïve Patients with Ulcerative Colitis: A Real-World Propensity-Weighted Comparison

J Crohns Colitis

Gros B, Constantine-Cooke N, Kennedy J, Elford AT, O'Hare C, Noble C, Jones GR, Arnott ID, Lees CW, Plevris N

doi: 10.1093/ecco-jcc/jjae188

Inflammatory Bowel Disease

Opioid Use and Outcomes in Patients Hospitalized With Acute Severe Ulcerative Colitis

Inflamm Bowel Dis

Karlovich N, McConnell R, Velayos F, Mahadevan U, Lewin S

doi: 10.1093/ibd/izae216

Inflammatory Bowel Disease

Real-world Effectiveness of Ustekinumab Versus Anti-TNF or Vedolizumab in Ulcerative Colitis: Induction and 12-Month Maintenance Results from the Prospective, Observational RUN-UC Study

J Crohns Colitis

Bokemeyer B, Plachta-Danielzik S, Gilman E, Howaldt S, Mohl W, Efken P, Ehehalt R, Kahl M, Krause T, Trentmann L, Lügering A, Schnoy E, Jochum C, Hartmann P, Schreiber S

doi: 10.1093/ecco-jcc/jjaf052

Inflammatory Bowel Disease

Real-world comparison of the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis: the TORUS study

Clin Gastroenterol Hepatol

Buisson A, Serrero M, Altwegg R, Guilmoteau T, Bouguen G, Nachury M, Amiot A, Vuitton L, Treton X, Caillo L, Pereira B, Fumery M

doi: 10.1016/j.cgh.2025.07.044

Inflammatory Bowel Disease

Tofacitinib for ulcerative colitis in Brazil: a multicenter observational study on effectiveness and safety

BMC Gastroenterol

Parra RS, de Sá Brito Fróes R, Magro DO, da Costa Ferreira S, de Mello MK, de Azevedo MFC, Damião AOMC, de Sousa Carlos A, Barros LL, de Miranda MLQ, Vieira A, Sales MPM, Zabot GP, Cassol OS, Tiburcio Alves AJ Jr, Lubini M, Machado MB, Flores C, Teixeira FV, Coy CSR, Zaltman C, Chebli LA, Sassaki LY, Féres O, Chebli JMF

doi: 10.1186/s12876-025-03656-x

Inflammatory Bowel Disease

Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study

Lancet Gastroenterol Hepatol

Panaccione R, Vermeire S, Danese S, Higgins PDR, Lichtenstein GR, Nakase H, Glover S, Colombel JF, Eccleston J, Kujawski M, Remple V, Yao X, Geng Z, Palac H, Sharma D, Suravaram S, Schreiber S

doi: 10.1016/S2468-1253(25)00017-2

Inflammatory Bowel Disease

Effectiveness of Ustekinumab for patients with moderate to severe Ulcerative Colitis: A Multi-Center Real-World Canadian Study

Am J Gastroenterol

Solitano V, Narula N, Ma C, Nanayakkara A, Suarez KE, Zoughlami A, Guizzetti L, Bessissow T, Jairath V

doi: 10.14309/ajg.0000000000003212

Related content

Real-World Experience with Upadacitinib for Pediatric Acute Severe Ulcerative Colitis: An International Multicenter Retrospective Study from the Pediatric IBD Porto Group of ESPGHAN

Intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis (PREDICT-UC): an open-label, multicentre, randomised controlled trial

Tofacitinib versus Vedolizumab Among Bio-naïve Patients with Ulcerative Colitis: A Real-World Propensity-Weighted Comparison

Opioid Use and Outcomes in Patients Hospitalized With Acute Severe Ulcerative Colitis

Real-world Effectiveness of Ustekinumab Versus Anti-TNF or Vedolizumab in Ulcerative Colitis: Induction and 12-Month Maintenance Results from the Prospective, Observational RUN-UC Study

Real-world comparison of the effectiveness of tofacitinib and ustekinumab in patients with ulcerative colitis: the TORUS study

Tofacitinib for ulcerative colitis in Brazil: a multicenter observational study on effectiveness and safety

Long-term efficacy and safety of upadacitinib in patients with moderately to severely active ulcerative colitis: an interim analysis of the phase 3 U-ACTIVATE long-term extension study

Effectiveness of Ustekinumab for patients with moderate to severe Ulcerative Colitis: A Multi-Center Real-World Canadian Study